Přehled o publikaci
2025
Targeting proteostasis in multiple myeloma through inhibition of LTK
VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE et. al.Basic information
Original name
Targeting proteostasis in multiple myeloma through inhibition of LTK
Authors
VATSVEEN, Thea Kristin; Mariaserena GILIBERTO; Valgerdur BJORNSDOTTIR; Federica CENTONZE; Andrej BEŠŠE; Yannick FREY; Sigrid S SKANLAND; Anders TVEITA; Amin ALIREZAYLAVASANI; John Franklin IMBERY; Kristine MISUND; Veronika REITERER; Muhammad ZAHOOR; Christoph DRIESSEN; Lenka BEŠŠE; Kjetil TASKEN; Fredrik H SCHJESVOLD; Hesso FARHAN and Ludvig A MUNTHE
Edition
Leukemia, London, Nature Publishing Group, 2025, 0887-6924
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001527724200001
EID Scopus
2-s2.0-105010413889
Keywords in English
multiple myeloma; LTK kinase; proteostasis; ALK inhibitors; immunoglobulin secretion
Links
LX22NPO5102, research and development project.
Changed: 21/11/2025 00:50, RNDr. Daniel Jakubík
Abstract
In the original language
Multiple myeloma (MM) cells secrete high levels of immunoglobulin and are therefore addicted to mechanisms that maintain proteome homeostasis (proteostasis). While proteasome inhibitors that target the degradative aspect of proteostasis have proven effective, only limited attempts have been made to target protein secretion. Here we show that the receptor tyrosine kinase LTK is a regulatory node in the proteostasis network that responds to secretory load and helps cells maintain a high secretory output. LTK is a highly similar paralog to ALK and by repurposing existing ALK inhibitors, we demonstrate that targeting LTK causes immunoglobulin retention, ER stress and subsequent apoptosis of primary MM cells, even in patients refractory to proteasome inhibitors. Thus, LTK is a novel therapeutic target in the biosynthetic pathway of proteostasis, with significant potential for MM treatment.